Boltz raises $110M Series A
London-based AI drug discovery startup Boltz has raised a $110 million Series A funding round, less than a year after emerging out of stealth. Bessemer Venture Partners led the round, with existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures participating.
New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling, joining Nvidia, which also announced an investment earlier this year during Jensen Huang’s visit to the UK. It follows Boltz raising a $28 million seed round at the start of the year.
Boltz was spun out of MIT in the US but is now located in London, employing 40 AI researchers in the capital’s King’s Cross district. The startup builds software which helps pharmaceutical and biotech researchers design potential drugs and decide which candidates to test in labs.
At MIT, the co-founders released open-source AI models that matched the performance of closed-source models like DeepMind’s AlphaFold3. These models are now part of the default setting for early-stage drug discovery. Boltz has also announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb.
Revenue is generated through partnerships and providing access to its platform and models, and the company said it will use the funding to invest in compute and data, and expand its team.
Boltz said: “We believe we are still just at the beginning of an exponential trajectory in model capabilities. Our upcoming models are already showing substantial improvements in the quality of the molecules they generate. Our long-term goal remains a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer. Reaching that goal will require further advances in the models and substantial investment in compute and data.”
